The effect of leflunomide on the variation of clinical and laboratory parameters on patients suffering from rheumatismal arthritis at active stage and the monitoring of side effects were studied in a 6 month opening non-comparing clinical investigation at 4 institutions in Vietnam. Oral leflunomide was administered 1 tablet (100mg) daily in the first 3 day, then 20mg daily in 6 months continuously. Results showed that clinical testing mean parameters reduced by 28-77% after 2 months and 57-83% after 6 months. In 21.4% of patients, at least 1 side effect manifested at light to moderate level
Arthritis, Rheumatoid ; Arthritis ; Rheumatoid Factor